Doximity stock has had a difficult five year stretch, with shareholders seeing the share price decline 71.8%, even as recent AI driven products have drawn fresh attention. At the current price near US$24.94, the key issue is whether the latest enthusiasm lines up with what the intrinsic value and market based checks say about Doximity. Over five years, the share price decline of 71.8% points to investors reassessing what they are willing to pay for Doximity. Growth expectations around...

Doximity (DOCS) is back in focus after its latest quarterly report showed higher sales, raised full year revenue guidance, and continued margin pressure tied to heavier spending on AI tools. See our latest analysis for Doximity. At a share price of US$24.94, Doximity has seen a 30 day share price return of 15.89% and a 90 day share price return of 25.58%. However, the year to date share price return is down 42.39% and the 1 year total shareholder return is down 60.79%. This points to...

This sale was executed under a pre-established Rule 10b5-1 trading plan adopted in February.

Sitaram's sale was driven by tax obligations from option exercises and RSU vesting, not a shift in conviction.

Restricted stock unit vesting triggered a routine sell-to-cover sale, reducing Zatz's direct holdings by 8% while leaving him with $1.3 million in remaining equity.

This non-discretionary sale tied to restricted stock unit vesting reduced the CFO's direct holdings by 3%, though he retains a $12.1 million equity stake in the healthcare platform operator.

Tangney executed a non-discretionary sale to cover tax withholding on vesting equity awards.

A number of stocks jumped in the afternoon session after the Bureau of Labor Statistics reported that the July Producer Price Index was completely flat month-over-month—coming in below expectations for a 0.2% increase—following the Consumer Price Index print (released earlier in the week) which showed a mild 0.1% monthly increase and an annual inflation rate cooling to 3.4%. Together, the data points suggest price pressures are moderating across both wholesale and consumer levels, taking the urg

Doximity’s second quarter results were met with a notably positive market reaction following revenue that surpassed Wall Street expectations and ongoing momentum in its healthcare professional network. Management attributed the quarter’s growth to increased adoption of AI-powered clinical tools and rising engagement from both hospital and pharmaceutical clients. CEO Jeffrey Tangney highlighted, “Quarterly active workflow prescribers grew more than 30% year-on-year to record highs with nearly hal

Revenue grew 7% as AI adoption accelerated, with AI Scribe users surging 10-fold in July.